These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 34339865)
1. The use of real-world data/evidence in regulatory submissions. Song F; Zang C; Ma X; Hu S; Sun Q; Chow SC; Sun H Contemp Clin Trials; 2021 Oct; 109():106521. PubMed ID: 34339865 [TBL] [Abstract][Full Text] [Related]
2. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions. Wu J; Wang C; Toh S; Pisa FE; Bauer L Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065 [TBL] [Abstract][Full Text] [Related]
3. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases. Vaghela S; Tanni KA; Banerjee G; Sikirica V Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874 [TBL] [Abstract][Full Text] [Related]
5. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making. Yuan L; Rahman M; Concato J Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484 [TBL] [Abstract][Full Text] [Related]
6. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment. Timbie JW; Kim AY; Concannon TW Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277 [TBL] [Abstract][Full Text] [Related]
7. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. Klonoff DC J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182 [TBL] [Abstract][Full Text] [Related]
8. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs. Zettler ME Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688 [TBL] [Abstract][Full Text] [Related]
9. Examining the Use of Real-World Evidence in the Regulatory Process. Beaulieu-Jones BK; Finlayson SG; Yuan W; Altman RB; Kohane IS; Prasad V; Yu KH Clin Pharmacol Ther; 2020 Apr; 107(4):843-852. PubMed ID: 31562770 [TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective. Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C; Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555 [TBL] [Abstract][Full Text] [Related]
11. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements. Sievers H; Joos A; Hiligsmann M Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423 [TBL] [Abstract][Full Text] [Related]
12. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics. Bloomfield-Clagett B; Rahman M; Smith K; Concato J Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904 [TBL] [Abstract][Full Text] [Related]
13. Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review. Seifu Y; Gamalo-Siebers M; Barthel FM; Lin J; Qiu J; Cooner F; Ruan S; Walley R Ther Innov Regul Sci; 2020 Nov; 54(6):1436-1443. PubMed ID: 32514737 [TBL] [Abstract][Full Text] [Related]
14. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims. Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517 [TBL] [Abstract][Full Text] [Related]
15. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks. Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G Ther Innov Regul Sci; 2024 Nov; 58(6):1042-1052. PubMed ID: 39060838 [TBL] [Abstract][Full Text] [Related]
16. Trial designs using real-world data: The changing landscape of the regulatory approval process. Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482 [TBL] [Abstract][Full Text] [Related]
17. Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union. Zou KH; Berger ML Bioengineering (Basel); 2024 Aug; 11(8):. PubMed ID: 39199742 [TBL] [Abstract][Full Text] [Related]
18. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned. Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264 [TBL] [Abstract][Full Text] [Related]
19. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330 [TBL] [Abstract][Full Text] [Related]
20. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea. Lee H; Ahn HS; Kwon S; Kang HY; Han E Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]